key: cord-0698238-uq251osd
authors: Baiou, Anas; Elbuzidi, Abdurrahman A.; Bakdach, Dana; Zaqout, Ahmed; Alarbi, Khalid M.; Bintaher, Awadh A.; Ali, Maisa M.B.; Elarabi, Anam M.; Ali, Gawahir A.M.; Daghfal, Joanne; Almaslamani, Muna A.; Ibrahim, Abdul Salam S.; Alkhal, Abdullatif; Omrani, Ali S.
title: Clinical characteristics and risk factors for the isolation of multidrug-resistant Gram-negative bacteria from critically ill patients with Coronavirus Disease 2019
date: 2021-02-06
journal: J Hosp Infect
DOI: 10.1016/j.jhin.2021.01.027
sha: 22b3e83c2c0b59d0948ddec77d80efcc1fa3f43d
doc_id: 698238
cord_uid: uq251osd

BACKGROUND: We investigated the clinical characteristics and risk factors for the isolation of multidrug resistant (MDR) Gram-negative bacteria (GNB) from critically ill COVID-19 patients. METHODS: We retrospectively matched (1:2) critical COVID-19 patients with one or more MDR GNB from any clinical specimen (cases), with those with no MDR GNB isolates (controls). RESULTS: Seventy-eight cases were identified (4.5 per 1,000 ICU days, 95% confidence interval [CI] 3.6–5.7). Out of 98 MDR GNB isolates, the most frequent species were Stenotrophomonas maltophilia (24, 24.5%), and Klebsiella pneumoniae (23, 23.5%). Two (8.7%) K. pneumoniae, and six (85.7%) Pseudomonas aeruginosa isolates were carbapenem resistant. A total of 24 (24.5%) isolates were not considered to be associated with active infection. Those with active infection received appropriate antimicrobial agent within a median of one day. The case group had significantly longer median central venous line days, mechanical ventilation days, and hospital length of stay (P<0.001 for each). All-cause mortality at 28 days was not significantly different between the two groups (P = 0.19). Mechanical ventilation days (adjusted odds ratio [aOR] 1.062, 95% CI 1.012 to 1.114; P 0.015), but not receipt of corticosteroids or tocilizumab, was independently associated with the isolation of MDR GNB. There was no association between MDR GNB and 28-day all-cause mortality (aOR 2.426, 95% CI 0.833 to 7.069; P = 0.104). CONCLUSION: In critically ill COVID-19 patients, prevention of MDR GNB colonization and infections requires minimising the use of invasive devices, and to remove them as soon as their presence is no longer necessary.

performed twice per day, and at patient transfer or discharge [8] . 117

Matrix-Assisted Laser Desorption/Ionization-Time of Flight (MALDI-TOF) mass 119 spectrometry (Bruker Corporation, Billerica, Massachusetts) was used for bacterial 120 identification. BD Phoenix™ (Becton, Dickinson and Company, Franklin Lakes, New Jersey, 121

United States) was used for antimicrobial susceptibility testing and for the detection of extended-122 spectrum beta-lactamases (ESBL). Clinical Laboratory Standards Institute breakpoints were used 123 [9] . When an MDR Gram-negative species was isolated from multiple sites or on multiple 124 occasions from the same patient, only the first isolate was included. 125

Procedures 126 GNB isolates were considered MDR if they expressed in vitro resistance to one or more 127 antimicrobial agents from three or more antimicrobial classes [10] . The National Healthcare 128 Safety Network definitions were used to define and classify bacterial infections [11] . 129

The electronic health records were used to identify patients who were aged 18 years or more, 130 had laboratory-confirmed COVID-19, and were admitted to ICU for 48 hours or more during the 131 period from 1 st March 2020 to 30 th June 2020. Cases were defined as those who had at least one 132 MDR GNB species isolated from any biological specimen taken during their ICU admission. 133

Controls were defined as those who did not have any MDR Gram-negative isolates during their 134 ICU stay. Cases and controls were matched in 1:2 ratio for their month of admission to ICU. 135

Starting from 1 st March 2020, consecutive patients who were eligible for inclusion were selected 136 until two controls were identified for each case. Study data were collected retrospectively during 137 the period from 15 th July 2020 to 14 th August 2020. The report was prepared according the 138 J o u r n a l P r e -p r o o f Table 1 . 179

The median hospital length of stay was 31.5 days (IQR 20-48) for the case group, and 20 180 days (IQR 15-30) for the control group (P<0.001). However, 12 (15.4%) from the case group 181 and 15 (9.6%) from the control group died of any cause within 28 days of admission to ICU (P = 182 0.19). Other clinical outcomes are shown in Table 1 . 183

In the unadjusted logistic regression analysis, several covariates showed statistically 184 significant associations with the isolation of MDR GNB; but mechanical ventilation days was the 185 only variable with a significant independent association (adjusted odds ratio 1.062, 95% CI 1.012 186 to 1.114; P = 0.015) ( Table 2 ). The isolation of MDR GNB was not associated with 28-day all-187 cause mortality (adjusted odds ratio 2.426, 95% CI 0.833 to 7.069; P = 0.104) (Table S1 and 188 Table S2 , data supplement file). 189

We herein report the rate and risk factors for the isolation of MDR GNB from a national 191 cohort of critically ill COVID-19 patients. The most frequently identified MDR pathogen was S. No funding was received to assist with the preparation of this manuscript.. 268

The authors have no conflicts of interest to declare that are relevant to the content of this article. 270

The datasets used and analysed during the current study are available from the corresponding 272 author on reasonable request. 

World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard

COVID-19 pandemic -a focused review for clinicians

Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid 280 review and meta-analysis

Co-infections in people with COVID-19: a 283 systematic review and meta-analysis

COVID-19 patients: A matter of concern

Microbiological and clinical aspects of infection associated with 314

Stenotrophomonas maltophilia

Antibiotic use in patients with COVID-19: a 'snapshot' Infectious Diseases International 318

Research Initiative (ID-IRI) survey

Intensive care management 321 of coronavirus disease 2019 (COVID-19): challenges and recommendations

Hospital 324 surge capacity in a tertiary emergency referral centre during the COVID-19 outbreak in 325

Infection prevention and control in nursing severe coronavirus 327 disease (COVID-19) patients during the pandemic

Universal glove 330 and gown use and acquisition of antibiotic-resistant bacteria in the ICU: a randomized 331 trial

Do contact precautions reduce the incidence of ICU-acquired Pseudomonas 334 aeruginosa infections? The DPCPYO cluster-randomized crossover trial

Contact 337 precautions: more is not necessarily better